

RESEARCH RESULTS

GLP-1 Pharmacy Targeting

GLP-1 Economics | Pharmacy Scoring | Outreach Priority

RETAILMYMEDS

PREPARED FOR **Arica Collins, PharmD & Kevin McCarron**

PREPARED BY **Matthew Scott**

February 2026 | v1.0



What This Is

I ran research against publicly available federal datasets to answer a specific question: **which of the 41,775 qualified independent pharmacies in the database are the strongest targets for RetailMyMeds, and why?**

The result is a single CSV (`pharmacies_glp1_targeting.csv`) that scores and ranks every pharmacy by estimated GLP-1 financial exposure, area-level health data, and outreach priority. Every number traces to a named federal source.

The underlying data is measured — federal agency datasets, not survey self-reports. The financial projections layered on top are *estimates* built from that data using NCPA's published loss-per-fill economics.^{1,2} Where a number is measured vs. estimated is noted throughout.

Data Sources

Source	What It Provides	Agency
Medicare Part D³	State GLP-1 claims + drug cost (2023)	CMS
Medicaid SDUD⁴	State GLP-1 prescriptions + reimbursement (2024)	CMS
CDC PLACES 2025⁵	ZIP-level diabetes, obesity, uninsured rates	CDC
Census ACS 2023⁶	ZIP-level % 65+, median income, population	Census Bureau
HRSA HPSA 2026⁷	Primary care shortage area designations	HRSA
NPPES NPI Registry⁸	Pharmacy identity, status, owner	CMS

Loss-per-fill economics (\$37–\$42/fill) come from NCPA survey data^{1,2} and per-drug WAC-minus-reimbursement calculations from the GLP-1 Value Proposition. The \$275/month subscription price and 5% moderate routing rate come from the RetailMyMeds GLP-1 Value Proposition.

How the Scoring Works

Each pharmacy receives a **final score (0–100)** from three weighted components:

Component	Weight	What It Measures
Opportunity Score	45%	Area disease burden (diabetes + obesity), Medicare density (% 65+), state GLP-1 market intensity, HPSA underserved status
Financial Impact	30%	Magnitude of estimated monthly GLP-1 loss (\$)
Urgency	25%	GLP-1 fill volume, disease severity, MFP exposure, shortage area acuity

Why these weights. Opportunity captures whether the pharmacy is *in the right area* — high disease burden means more GLP-1 demand, more 65+ means more Part D exposure, HPSA means less competition. Financial impact captures how much the pharmacy is *bleeding today*. Urgency captures how *acutely* they need a solution. A pharmacy can be in a perfect area (high opportunity) but with moderate volume (lower financial impact) — or vice versa. The weighted blend identifies pharmacies where all three align.

FILL ESTIMATE METHODOLOGY

Monthly GLP-1 fills per pharmacy are estimated by indexing each state's CMS-measured claims volume^{3,4} against the NCPA national average of 394 GLP-1 fills/month,⁹ then adjusting $\pm 15\%$ based on the pharmacy's ZIP-level disease burden⁵ and Medicare density.⁶ The resulting range (197–650 fills/month) aligns with the 80–580 range observed in the 12-pharmacy portfolio analysis.

Results

Grade Distribution

Grade	Count	% of Total	Classification
A	5,118	12.3%	Strong Fit — high area need + high financial exposure + high urgency
B	14,775	35.4%	Good Fit — strong on two of three dimensions
C	18,352	43.9%	Conditional — moderate opportunity, worth monitoring
D	3,530	8.5%	Low priority — low volume or low area need

Outreach Priority

Priority	Count	%	Action
Immediate Outreach	11,190	26.8%	Direct outreach — final score ≥ 80
Nurture	10,949	26.2%	Drip campaign, conference touchpoints — score 70–79
Conditional	16,106	38.6%	Watch list — score 55–69, may convert as MFP cycles expand
Deprioritize	3,530	8.5%	Score below 55 — do not spend time here

Conversation Segments

Each pharmacy is tagged with the pain point that should lead the conversation:

Segment	Count	Lead Message
GLP-1 Loss	30,808 (73.7%)	“You’re losing \$37–\$42 on every GLP-1 fill. RetailMyMeds routes those prescriptions so you stop absorbing the loss.”
DIR Fee Squeeze	7,424 (17.8%)	“Your area is medically underserved and your margins are the thinnest in the country. Routing below-cost prescriptions is how you survive.”
MFP Cash Flow	3,543 (8.5%)	“MFP is creating a \$10,838/week cash flow gap. RetailMyMeds’ scheduling intelligence addresses the timing directly.”

Financial Model

Every pharmacy in the CSV includes a per-pharmacy financial projection. “ROI multiple” = estimated annual net savings / \$3,300 annual subscription cost, assuming 5% of GLP-1 fills are

routed at the mid-range loss of \$39.50/fill. This is a projected return on the subscription, not a guaranteed outcome — actual results depend on the pharmacy's real fill volume and PBM contracts.

IMMEDIATE OUTREACH PHARMACIES — AVERAGE PROFILE

Estimated monthly GLP-1 fills: **~484**

Estimated monthly GLP-1 loss (mid): **~\$19K** (\$10K–\$26K range)

At 5% routing rate (~24 fills routed): **~\$680/month net savings** after \$275 subscription

Estimated ROI multiple: **2.5x** (range: 0.9x–3.6x)

Breakeven: **8 fills/month** routed (~2% of GLP-1 volume)

These are estimates, not pharmacy-reported numbers. The national average pharmacy (394 fills/month at \$39.50/fill mid-range loss) yields \$503/month net savings and 1.8x ROI per the GLP-1 Value Proposition.⁹ Immediate Outreach pharmacies score higher because they are in areas with above-average disease burden and Medicare density, which the model uses to estimate higher fill volume.

The CSV includes three loss scenarios per pharmacy:

Scenario	Loss/Fill	Source
Conservative	\$37/fill	Per-drug WAC/reimbursement spread ^{1,9}
Mid-range	\$39.50/fill	Midpoint
High	\$42/fill	NCPA pharmacist survey ²

Top 10 States by Immediate Outreach Volume

Rank	State	Imm. Outreach	Est. Avg Loss/Mo	Est. ROI
1	California	2,070	~\$20K	2.6x
2	North Carolina	883	~\$18K	2.3x
3	Ohio	842	~\$25K	3.6x
4	Louisiana	759	~\$20K	2.5x
5	Illinois	671	~\$17K	2.1x
6	Tennessee	574	~\$15K	1.8x
7	Missouri	437	~\$15K	1.8x
8	South Carolina	395	~\$18K	2.2x
9	West Virginia	356	~\$19K	2.4x
10	Wisconsin	354	~\$21K	2.8x

Louisiana is highlighted as Arica's home market. Ohio and Wisconsin show the highest per-pharmacy loss among the top 10, making them strong expansion targets.

What's in the CSV

`pharmacies_glp1_targeting.csv` contains **36 columns** per pharmacy:

Identity (9 fields)

- NPI, name, city, state, ZIP, phone
- NPPES status, owner name, owner title

Area Health Context (7 fields)

- ZIP diabetes %, obesity %, % 65+
- Median income, population
- HPSA designated (yes/no), HPSA score

State GLP-1 Economics (2 fields)

- Govt GLP-1 claims per pharmacy
- Govt GLP-1 cost per pharmacy

Pharmacy Financial Estimates (5 fields)

- Est. monthly GLP-1 fills
- Monthly loss (low / mid / high)
- Annual loss

ROI Model (7 fields)

- Fills routed at 5%, monthly savings
- Net monthly after \$275 subscription
- Annual net savings, ROI multiple
- Breakeven fills, % volume for breakeven

Targeting (6 fields)

- Segment (GLP-1 / MFP / DIR)
- Urgency score, opportunity score
- Final score, grade, outreach priority

What This Means

The 41,775 pharmacies in the qualified database now have **measured, source-cited targeting data**. For Arica's outreach:

1. **11,190 pharmacies are flagged Immediate Outreach.** These are independents in high-disease-burden, high-Medicare-density areas with the highest estimated GLP-1 losses. They are the pharmacies most likely to feel the pain RetailMyMeds solves.
2. **Every pharmacy has a conversation segment.** The CSV tells you whether to lead with GLP-1 losses, MFP cash flow, or DIR fee pressure — based on that pharmacy's area characteristics, not a guess.
3. **The financial model is per-pharmacy, not per-state.** Each row shows estimated fills, estimated losses, projected savings at \$275/month, and estimated ROI. This applies the same math from the GLP-1 Value Proposition to each pharmacy's area context. The base case (394 fills, \$37/fill, 5% routing) yields \$465/month net — higher-scoring pharmacies project higher because their area data suggests above-average GLP-1 volume.
4. **Louisiana has 759 Immediate Outreach pharmacies** with an average estimated loss of ~\$20K/month and 2.5x estimated ROI. This is Arica's home market, supported by the WVIPA relationship and association expansion strategy.
5. **This data feeds the qualification system Kevin is building on the site.** The targeting database identifies which pharmacies to reach. When those pharmacies engage — through Arica's outreach or through the website — the qualification form scores them using the same dimensions (financial exposure, operational readiness, market urgency) and delivers a personalized scorecard. The database is the prospect list; the website is the conversion point.

CONCRETE NEXT STEP

In the CSV, filter `outreach_priority = "Immediate Outreach"` and `state = "LA"` to get Arica's first 759 call targets, sorted by `final_score` descending. The `segment` column tells you which pain point to lead with for each pharmacy.

HONEST FRAMING

What is measured: NPI/pharmacy identity (NPPES⁸), ZIP-level disease prevalence (CDC PLACES⁵), % 65+ and income (Census ACS⁶), HPSA designations (HRSA⁷), state-level GLP-1 claims and costs (CMS Medicare Part D³, Medicaid SDUD⁴).

What is estimated: Per-pharmacy GLP-1 fill volume (derived from state CMS data indexed to the NCPA 394/month average,⁹ adjusted ±15% by area health burden), monthly loss (fills × \$37–\$42 NCPA loss/fill^{1,2}), savings (assumes 5% routing rate from Value Proposition), and ROI (savings / \$3,300 annual subscription).

Key assumptions in the estimation chain: Government payers represent ~55% of GLP-1 volume; state index is capped at 1.5x national average; area disease burden adjusts fills ±15%; 5% routing rate is the moderate scenario, not guaranteed.

Actual conversion depends on the pharmacy's specific PBM contracts, real fill volume, and willingness to adopt.

Sources

¹ NCPA, “Local pharmacies say they’re struggling to afford GLP-1s,” November 1, 2023. Reports \$37+ average losses per 30-day supply and 88% of pharmacies considering discontinuing GLP-1 dispensing. Per-drug WAC/reimbursement spread confirms \$20–\$42 loss range across Ozempic, Wegovy, Mounjaro, and Zepbound.

<https://ncpa.org/newsroom/qam/2023/11/01/local-pharmacies-say-theyre-struggling-afford-glp-1s>

² NCPA pharmacist survey, 2023. 95% of respondents reported being paid an average of \$42 below acquisition cost on GLP-1 fills. 73% reported turning away patients due to losses.

<https://ncpa.org/newsroom/qam/2023/11/01/local-pharmacies-say-theyre-struggling-afford-glp-1s>

³ CMS, Medicare Part D Spending by Drug, 2023. State-level GLP-1 claims volume and gross drug cost.

<https://data.cms.gov/summary-statistics-on-use-and-payments/medicare-medicaid-spending-by-medicare-part-d-spending-by-drug>

⁴ CMS, Medicaid State Drug Utilization Data (SDUD), 2024. State-level GLP-1 prescriptions and reimbursement amounts.

<https://www.medicaid.gov/medicaid/prescription-drugs/state-drug-utilization-data>

⁵ CDC, PLACES: Local Data for Better Health, 2025 Release. ZIP-level model-based estimates for diabetes prevalence, obesity prevalence, and other chronic disease indicators.

<https://www.cdc.gov/places/index.html>

⁶ U.S. Census Bureau, American Community Survey 5-Year Estimates, 2019–2023. ZIP-level % age 65+, median household income, and population.

<https://data.census.gov/all?y=2023&d=ACS+5-Year+Estimates+Detailed+Tables>

⁷ HRSA, Health Professional Shortage Areas (HPSA), current as of January 2026. Primary care shortage area designations and HPSA scores.

<https://data.hrsa.gov/topics/health-workforce/shortage-areas>

⁸ CMS, National Plan and Provider Enumeration System (NPPES) NPI Registry. Pharmacy identity, taxonomy, status, and owner information.

https://download.cms.gov/nppes/NPI_Files.html

⁹ RetailMyMeds GLP-1 Routing Value Proposition, February 2026 (v1.0). 394 fills/month national average derived from 67,601 annual Rx at 7% GLP-1 penetration (NCPA Digest 2024). \$275/month pricing, 5% moderate routing rate, breakeven analysis.